glp-1 agonists addiction drugs may help curb by targeting reward pathways GLP-1s and Addiction Treatment: Setting

FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) are commercially available

Full dose or microdose

Rapid weight loss with GLP1 receptor agonists can come at the cost of skeletal muscle, potentially undermining metabolic and functional outcomes

For health-conscious individuals, supplements arent shortcuts, theyre strategic additions

These are serious prescription medicines not quick-fix weight loss solutions

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection